MS trial phase 2 enrollment complete - Tiziana CEO on the foralumab breakthrough

By Proactive Investors / May 22, 2026 / www.youtube.com / Article Link

Tiziana Life Sciences has completed enrollment in its Phase 2 trial of foralumab for secondary progressive multiple sclerosis.

Recent News

Mining sector far outpaces tech over past three years

September 21, 2026 / www.canadianminingreport.com

Gold stocks down with GDXJ outperforming on rebalancing

September 21, 2026 / www.canadianminingreport.com

Copper slides as US apparently wavering on tariff hikes

September 14, 2026 / www.canadianminingreport.com

Historically huge distortion in global copper inventory balance

September 14, 2026 / www.canadianminingreport.com

Gold stocks pause along with metal price

September 07, 2026 / www.canadianminingreport.com

See all >